Index -
P/E 37.02
EPS (ttm) 13.45
Insider Own 19.08%
Shs Outstand 28.02M
Perf Week 4.43%
Market Cap 13.99B
Forward P/E 31.83
EPS next Y 15.64
Insider Trans -2.97%
Shs Float 22.73M
Perf Month 7.54%
Enterprise Value 14.09B
PEG 3.58
EPS next Q 3.52
Inst Own 95.68%
Short Float 9.92%
Perf Quarter 67.10%
Income 418.30M
P/S 6.27
EPS this Y 11.14%
Inst Trans 2.96%
Short Ratio 4.53
Perf Half Y 54.16%
Sales 2.23B
P/B 80.93
EPS next Y 11.44%
ROA 23.96%
Short Interest 2.25M
Perf YTD 49.84%
Book/sh 6.15
P/C 301.87
EPS next 5Y 10.35%
ROE 89.38%
52W High 501.30 -0.69%
Perf Year 41.56%
Cash/sh 1.65
P/FCF 24.12
EPS past 3/5Y 37.94% 36.50%
ROIC 140.70%
52W Low 250.05 99.09%
Perf 3Y 196.10%
Dividend Est. -
EV/EBITDA 27.82
Sales past 3/5Y 22.68% 19.62%
Gross Margin 30.32%
Volatility 3.31% 2.40%
Perf 5Y 327.91%
Dividend TTM -
EV/Sales 6.31
EPS Y/Y TTM 25.30%
Oper. Margin 21.40%
ATR (14) 13.35
Perf 10Y -
Dividend Ex-Date -
Quick Ratio 0.43
Sales Y/Y TTM 9.94%
Profit Margin 18.74%
RSI (14) 64.96
Recom 3.36
Dividend Gr. 3/5Y - -
Current Ratio 0.43
EPS Q/Q 12.47%
SMA20 3.80%
Beta 1.40
Target Price 436.90
Payout 0.00%
Debt/Eq 0.87
Sales Q/Q 14.24%
SMA50 13.97%
Rel Volume 0.59
Prev Close 490.77
Employees 5900
LT Debt/Eq 0.72
Earnings Jul 21 AMC
SMA200 42.01%
Avg Volume 498.01K
Price 497.83
IPO Aug 11, 2016
Option/Short Yes / Yes
EPS/Sales Surpr. 3.94% 11.98%
Trades
Volume 294,603
Change 1.44%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-03-25 Downgrade
Rothschild & Co Redburn
Buy → Neutral
$474
Jul-29-25 Downgrade
UBS
Neutral → Sell
$305
Jul-23-25 Downgrade
TD Cowen
Hold → Sell
$366
Jun-24-25 Initiated
Barclays
Equal Weight
$300
Apr-22-25 Downgrade
William Blair
Outperform → Mkt Perform
Apr-14-25 Downgrade
TD Cowen
Buy → Hold
$328
Mar-24-25 Initiated
Leerink Partners
Market Perform
$330
Oct-23-24 Downgrade
Robert W. Baird
Outperform → Neutral
$413 → $349
Oct-14-24 Initiated
Redburn Atlantic
Buy
Sep-27-24 Downgrade
UBS
Buy → Neutral
$420 → $350
Sep-25-24 Downgrade
Jefferies
Buy → Hold
$415 → $345
Aug-01-24 Initiated
Truist
Hold
$415
May-29-24 Initiated
TD Cowen
Buy
$452
May-28-24 Initiated
Mizuho
Buy
$435
Apr-23-24 Upgrade
Jefferies
Hold → Buy
$340 → $450
Mar-18-24 Initiated
Deutsche Bank
Hold
$395
Feb-15-24 Upgrade
UBS
Neutral → Buy
$282 → $452
Oct-24-23 Upgrade
Robert W. Baird
Neutral → Outperform
$270 → $289
May-08-23 Upgrade
Guggenheim
Neutral → Buy
$252
Oct-27-22 Upgrade
UBS
Sell → Neutral
$142 → $238
Show Previous Ratings
Today 10:41AM
08:51AM
08:50AM
Sep-16-25 11:40AM
10:26AM
09:34AM
Loading…
09:34AM
Sep-15-25 06:15PM
12:34PM
Sep-12-25 03:49AM
Sep-11-25 12:24PM
12:20PM
09:45AM
08:24AM
Sep-10-25 12:35PM
09:02AM
01:25PM
Loading…
Sep-09-25 01:25PM
08:45AM
Sep-08-25 07:34PM
12:36PM
08:14AM
08:07AM
Sep-05-25 12:30PM
11:31AM
10:56AM
08:06AM
Sep-04-25 11:40AM
Sep-03-25 01:23PM
08:50AM
Sep-02-25 01:32PM
Sep-01-25 12:53PM
09:54AM
Loading…
09:54AM
09:51AM
Aug-29-25 12:24PM
09:47AM
09:47AM
Aug-28-25 11:40AM
10:24AM
08:14AM
Aug-27-25 12:25PM
08:29AM
Aug-25-25 12:52PM
Aug-22-25 01:30PM
12:03AM
Aug-21-25 01:33PM
01:30PM
10:12AM
Aug-20-25 01:24PM
Aug-19-25 12:56PM
(Investor's Business Daily)
10:13AM
09:48AM
08:50AM
Aug-18-25 12:00PM
Aug-15-25 10:04AM
(Investor's Business Daily)
Aug-14-25 02:50PM
(Investor's Business Daily)
11:17AM
11:05AM
Aug-13-25 12:58PM
08:22AM
Aug-12-25 06:46PM
11:41AM
10:37AM
08:27AM
08:25AM
08:22AM
08:21AM
Aug-11-25 08:27AM
07:53AM
Aug-08-25 12:11PM
12:07PM
09:45AM
08:47AM
Aug-07-25 11:06AM
08:22AM
Aug-06-25 01:11PM
01:08PM
01:02PM
10:39AM
10:39AM
10:28AM
09:05AM
Aug-04-25 12:06PM
09:55AM
Aug-01-25 06:56PM
12:07PM
07:51AM
Jul-31-25 01:27PM
01:25PM
01:18PM
09:55AM
07:59AM
Jul-30-25 12:51PM
Jul-29-25 02:26PM
01:02PM
Jul-28-25 12:00PM
10:00AM
07:47AM
01:31AM
Jul-25-25 07:48PM
08:50AM
Jul-23-25 01:11PM
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BURWIG SUSAN E Exec. VP, Operations Sep 03 '25 Sale 480.00 10,000 4,800,000 57,500 Sep 05 04:16 PM BURWIG SUSAN E Officer Sep 03 '25 Proposed Sale 480.00 10,000 4,800,019 Sep 03 04:49 PM Troendle August J. CEO Aug 29 '25 Sale 475.90 36,196 17,225,676 925,799 Sep 03 04:10 PM Troendle August J. CEO Sep 02 '25 Sale 475.11 1,197 568,707 924,602 Sep 03 04:10 PM Troendle August J. CEO Aug 27 '25 Sale 475.00 620 294,500 961,995 Aug 28 04:23 PM BURWIG SUSAN E Exec. VP, Operations Aug 26 '25 Option Exercise 107.93 10,000 1,079,300 67,500 Aug 28 04:10 PM August J. Troendle Chairman Aug 27 '25 Proposed Sale 475.00 38,013 18,056,018 Aug 27 05:09 PM McCarthy Cornelius P. III Director Aug 19 '25 Sale 465.04 1,662 772,896 10,197 Aug 21 04:56 PM McCarthy Cornelius P. III Director Aug 19 '25 Proposed Sale 465.04 1,662 772,894 Aug 19 03:00 PM EWALD STEPHEN P General Counsel & Corp. Secy. Jul 28 '25 Sale 450.00 3,000 1,350,000 10,343 Jul 29 06:02 PM BURWIG SUSAN E Exec. VP, Operations Jul 28 '25 Sale 450.14 7,500 3,376,050 57,500 Jul 29 05:43 PM Troendle August J. CEO Jul 28 '25 Sale 451.69 48,487 21,901,093 962,615 Jul 29 05:37 PM GEIGER JESSE J President Jul 24 '25 Option Exercise 107.93 41,801 4,511,582 78,304 Jul 28 05:37 PM GEIGER JESSE J President Jul 24 '25 Sale 453.11 41,801 18,940,451 36,503 Jul 28 05:37 PM Brady Kevin M. CFO & Treasurer Jul 24 '25 Option Exercise 57.94 12,000 695,280 18,000 Jul 28 05:08 PM Brady Kevin M. CFO & Treasurer Jul 24 '25 Sale 454.23 12,000 5,450,760 6,000 Jul 28 05:08 PM BURWIG SUSAN E Officer Jul 28 '25 Proposed Sale 450.14 7,500 3,376,083 Jul 28 04:50 PM August J. Troendle Chairman Jul 28 '25 Proposed Sale 451.68 356,446 161,001,311 Jul 28 04:35 PM EWALD STEPHEN P Officer Jul 28 '25 Proposed Sale 450.00 3,000 1,350,000 Jul 28 03:27 PM McCarthy Cornelius P. III Director Jul 22 '25 Option Exercise 54.99 1,972 108,440 11,859 Jul 24 04:31 PM Brady Kevin M. Officer Jul 24 '25 Proposed Sale 454.23 12,000 5,450,751 Jul 24 04:13 PM GEIGER JESSE J Officer Jul 24 '25 Proposed Sale 453.11 41,801 18,940,252 Jul 24 04:09 PM McCarthy Cornelius P. III Director Jul 18 '25 Option Exercise 54.99 4,500 247,455 9,887 Jul 22 04:36 PM DAVENPORT FRED B JR Director Apr 24 '25 Option Exercise 57.17 4,710 269,271 4,710 Apr 28 04:39 PM DAVENPORT FRED B JR Director Apr 24 '25 Sale 301.82 1,712 516,716 2,998 Apr 28 04:39 PM DAVENPORT FRED B JR Director Apr 24 '25 Proposed Sale 301.82 1,712 516,716 Apr 24 02:13 PM Troendle August J. CEO Mar 07 '25 Option Exercise 68.62 356,446 24,458,835 1,011,102 Mar 10 05:47 PM EWALD STEPHEN P General Counsel & Corp. Secy. Feb 27 '25 Buy 326.11 2 652 13,343 Feb 28 04:39 PM Carley Brian T Director Feb 24 '25 Option Exercise 42.62 8,127 346,373 30,035 Feb 26 04:18 PM Carley Brian T Director Feb 24 '25 Sale 345.59 4,003 1,383,397 26,032 Feb 26 04:18 PM Carley Brian T Director Feb 24 '25 Proposed Sale 345.59 4,003 1,383,385 Feb 24 12:52 PM GEIGER JESSE J President Dec 06 '24 Option Exercise 32.05 15,000 480,750 36,503 Dec 10 04:24 PM BURWIG SUSAN E Exec. VP, Operations Nov 19 '24 Option Exercise 32.05 7,500 240,375 65,000 Nov 21 04:40 PM